We still don't know (and may never know) whether the artifact problem was *the* problem. It seems to me that cor believed it had adressed that problem, and that's why everybody was so optimistic last spring/summer.
The FDA may have shut down CX-717 simply because they didn't want to bring a new class of compounds to market for a non-lethal indication that primarily affects young people, and must be taken chronically.
This isn't even so unreasonable of the FDA. For a class of compounds that can be used to treat such a wide range of neurodegenerative/psychiatric diseases, I can't figure out why they lead with ADHD. RD makes much more sense: few alternatives (naloxone); acute use; life-threatening condition. If the April trials are succesful, I think it is less likely we will have an unpleasant surprise from the FDA.
News 
Market Data 
Discover 
AI
